Patents by Inventor Stuart Chambers

Stuart Chambers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 9006237
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 14, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Methods of neural conversion of human embryonic stem cells
    Patent number: 8642334
    Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: February 4, 2014
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Stuart Chambers, Lorenz Studer
  • Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases
    Publication number: 20120232075
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 13, 2012
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8178530
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 15, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8173656
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • METHODS OF NEURAL CONVERSION OF HUMAN EMBRYONIC STEM CELLS
    Publication number: 20120094381
    Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
    Type: Application
    Filed: February 17, 2010
    Publication date: April 19, 2012
    Inventors: Stuart Chambers, Lorenz Studer
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8148369
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: April 3, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8138193
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R1, R2, R8 and R9 as defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: March 20, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8133895
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: March 13, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110218178
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: September 8, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8012983
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: September 6, 2011
    Assignee: Galapagos NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Hervé Van De Poël, Grégory Louis Joseph Bar
  • TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110178067
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Application
    Filed: January 9, 2011
    Publication date: July 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus Macleod
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110092497
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: April 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7915256
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Grant
    Filed: March 8, 2009
    Date of Patent: March 29, 2011
    Assignee: Galapagos NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus MacLeod
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7893058
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 22, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES
    Publication number: 20100298300
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Application
    Filed: March 8, 2009
    Publication date: November 25, 2010
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus MacLeod
  • FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20100240666
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R1, R2, R8 and R9 as defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Application
    Filed: April 2, 2010
    Publication date: September 23, 2010
    Inventors: Martin James Inglis ANDREWS, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20090286798
    Abstract: Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 19, 2009
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Hervé Van De Poël, Grégory Louis Joseph Bar
  • Arylsulfonylnaphthalene derivatives as 5HTantagonists
    Patent number: 7592456
    Abstract: Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: September 22, 2009
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Mark Stuart Chambers, Neil Roy Curtis, Emanuela Gancia, Myra Gilligan, Alexander Charles Humphries, Tamara Ladduwahetty, Robert James Maxey, Kevin John Merchant
  • Novel compounds useful for the treatment of degenerative & inflamatory diseases
    Publication number: 20090137549
    Abstract: The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.
    Type: Application
    Filed: November 8, 2007
    Publication date: May 28, 2009
    Inventors: Paul John Edward, Mark Stuart Chambers, Christel Jeanne Marie Menet, Stephen Robert Fletcher, Rebecca Elizabeth Jarvis, Herve Van De Poel, Alexander Sudau, Alastair Rae, Peter Stanley Thomas